timothy sykes logo
CAPR Stock Jumps As Analysts Hike Targets Ahead Of FDA Date Thumbnail
G Google News

CAPR Stock Jumps As Analysts Hike Targets Ahead Of FDA Date

JACK KELLOGG•UPDATED SEP. 30, 2026, 7:48 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Capricor Therapeutics Inc. stocks have been trading up by 12.84 percent after promising clinical trial news boosted investor optimism.

Key Takeaways

  • B. Riley upgraded Capricor Therapeutics to Buy from Neutral and raised its price target from $5 to $21 ahead of the 2026/11/22 FDA action date for deramiocel and potential data at the 2026/10/03 World Muscle Society conference.
  • Shares popped about 5.1% after the B. Riley upgrade and sharp price target hike.
  • Piper Sandler upgraded Capricor Therapeutics to Overweight from Neutral and boosted its target from $2 to $25, citing attractive risk/reward into the extended FDA timeline for deramiocel.
  • Following the Piper Sandler call, the stock rose roughly 4.5% as traders responded to the bullish shift.
  • Street data show an average Overweight rating on Capricor Therapeutics with a mean target of $31.78, while a new Schedule 13G revealed a significant passive stake in CAPR.

Candlestick Chart

Live Update At 07:47:46 EDT: On Wednesday, September 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 12.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics (CAPR) trades like a classic biotech catalyst name right now. The daily chart shows CAPR bouncing between roughly $8.30 and $9.50 over the past couple of weeks, with a recent close near $8.57. That’s a tight range considering the wave of analyst upgrades, which tells traders the stock is consolidating after prior spikes.

Intraday, CAPR showed serious volatility, ripping from just under $10 at 04:00 to above $12 in the first hour before fading back toward the low $11s and then dipping under $10 later in the morning. For day traders, that’s a clean momentum setup: big morning push, then a series of lower highs as profit‑taking hits.

More Breaking News

Fundamentally, CAPR is still a development‑stage biotech. The latest quarterly numbers show a net loss of about $40.7M and operating cash flow around negative $31.5M. Return on equity and assets are deeply negative, which is normal for a clinical‑stage story. The key positive for Capricor Therapeutics is its balance sheet: more than $237.9M in cash and short‑term investments, a current ratio near 7.4, and modest debt. That runway matters as CAPR heads toward the 2026/11/22 FDA decision for deramiocel, the main driver behind the current trading focus.

Why Traders Are Watching CAPR Into The FDA Catalysts

CAPR has suddenly moved onto a lot more screens. The spark was a pair of aggressive analyst moves. B. Riley upgraded Capricor Therapeutics to Buy from Neutral and yanked its price target from $5 to $21, calling the risk/reward favorable into the 2026/11/22 FDA action date for deramiocel. That’s not a small bump; that’s a full re‑rating of how they see the story.

The market listened. CAPR jumped about 5.1% on that call, tacking onto earlier strength sparked when Piper Sandler went to Overweight from Neutral and raised its price target from $2 to $25. Any time you see a 10x target hike on a small‑cap biotech, you know sentiment has flipped. Traders chase that kind of shift because it often signals that key due‑diligence boxes have been checked on the Street side.

Under the surface, the catalysts are clear. Capricor Therapeutics is walking toward that 2026/11/22 FDA deadline for deramiocel, with an extra potential spark from open‑label extension data that might show up at the World Muscle Society meeting on 2026/10/03. Those dates define the trading calendar for CAPR. Between now and then, every rumor, abstract, or slide deck tied to deramiocel can move the stock.

It’s not just two firms talking, either. FactSet data cited in recent reports show Capricor Therapeutics carrying an average Overweight rating with a mean target near $31.78 — well above the $21 B. Riley mark and the $25 Piper Sandler level. Add in a new Schedule 13G filing that disclosed a significant passive ownership stake in CAPR, and you’ve got a picture of growing institutional interest. For momentum‑focused traders, that combination — bullish Street calls, visible catalysts, and fresh ownership — explains why CAPR is suddenly a hot ticker.

Conclusion

Right now CAPR sits at the intersection of charts and catalysts — exactly where active traders like to hunt. The stock is consolidating in the high‑$8s after sharp runs triggered by the B. Riley and Piper Sandler upgrades, while the average Street target up near $31.78 hangs far above current levels. Whether Capricor Therapeutics ever gets there will depend on one thing: how deramiocel looks when the FDA makes its call on 2026/11/22 and what data emerge around the 2026/10/03 World Muscle Society meeting.

Financially, Capricor Therapeutics is burning cash, but that’s expected for a clinical biotech. The difference is that CAPR has a sizable cash cushion and relatively low debt, which buys time to get through the deramiocel review. The new Schedule 13G shows at least one sizable player is comfortable sitting passively through that ride.

For traders, the job is to treat CAPR like any high‑beta catalyst play: map key dates, watch volume and range expansion, and manage risk like a pro. As Tim Sykes likes to remind his students, “The market rewards prepared traders, not hopeful gamblers.” As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. CAPR gives plenty of potential volatility; the edge comes from having a plan before the big headlines hit.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”